Predictive Biotech has finalized the development process of a new allograft stem cell product derived from UCB. Image source: www.explorestemcells.co.uk
Predictive Technology Group announces that its wholly-owned subsidiary, Predictive Biotech, has finalized the development process of a new allograft stem cell product derived from umbilical cord blood (UCB).
The use of UCB stem cells have gained popularity in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood and tissue that remains in the attached umbilical cord and placenta after childbirth. UCB derived stem cells are considered unique in their applicability in treating many different diseases and disorders such as fusion, wound healing, pain management and genetic and hematopoietic disorders.
Predictive Biotech is currently negotiating with several large orthobiologic distributors to launch the product domestically and internationally. The company is also considering private label opportunities and plans to eventually distribute the product through its own direct sales organization.
Predictive Technology Group
www.predictivetechnologygroup.com
